Clinical trial
Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild…
NCT00232999 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00232999 |
|---|---|
| Title | Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Collaborators | AllerGen NCE Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Nebulized IVX-0142 |
| Enrollment | 15 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Oct 5, 2005 |
| Last update posted | Nov 12, 2021 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: